Loading…
← CockpitCompetitor Analysis › 002821.SZ Asymchem Laboratories (Tianjin) Co., Ltd. Class AOpen in the cockpit ↗

Asymchem Laboratories (Tianjin) Co., Ltd. Class A002821.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese CDMO that manufactures small-molecule active ingredients and intermediates for global pharma and biotech under contract.

≈ A China-based Cambrex/Lonza for small-molecule APIsMomentum leader 85
Mkt cap
$7.27B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$181M
20-day average traded
Fwd P/E
37.4×
forward earnings
ROIC−WACC
+1.6 pp
WACC 9.5%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥141.21
1D-3.8%
1W-7.3%
1M-8.0%
3M-18.8%
6M+19.7%
YTD+52.0%
1Y+48.1%
ATR %6.2%
52w lowhigh29.4% off high

What Asymchem Laboratories (Tianjin) does

Chinese CDMO that manufactures small-molecule active ingredients and intermediates for global pharma and biotech under contract.

Customers hire it first to develop the manufacturing process for a drug in trials, which can lead to long commercial supply contracts if the drug is approved, so orders build over several years. COVID-treatment work temporarily boosted its sales during the pandemic. It is listed in both Shenzhen and Hong Kong.

In one line: A China-based Cambrex/Lonza for small-molecule APIs.

Products and services

  • Commercial API manufacturing
  • Process R&D / clinical-phase CDMO
  • Intermediates
  • Biologics & CGT CDMO

Customers

  • Global pharma innovators
  • US/EU biotech

Where it sits in the supply chain

  • Pharmaceuticals
  • Contract manufacturing (CDMO)
  • Small-molecule API & intermediates

What could go right

  • Pharma outsourcing shifting to Asia
  • New molecule wins from biotech pipelines

What could go wrong

  • US-China biosecurity/tariff scrutiny of CDMO
  • concentration in early-stage biotech clients

Moat: narrow (process know-how, customer qualification, regulatory licence). FDA/EMA-audited plants and validated processes make switching a qualified program costly.

Headquarters: Tianjin, China · Founded: 1995 · Employees: 10,617

Named competitors

Asymchem Laboratories (Tianjin) at a glance

Size Asymchem Laboratories (Tianjin) (002821.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $7.27B, the 322nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥141.21 on 18 Nov 2026.

Performance Over six months the shares gained 19.7%, against -0.4% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 18.1% over the last twelve months (peer median +8.5%); the operating margin is 17.2% (peer median 13.7%).

Valuation It trades at 37.4× forward earnings against a peer median of 19.2× (2nd most expensive of 16).

Capital Return on invested capital runs 1.6 points above its cost of capital (9.5% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026002821.SZ 119Peer median 101
Six months, rebased to 100: Asymchem Laboratories (Tianjin) against the median of its 20 peers (local-currency closes).

Asymchem Laboratories (Tianjin) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥7.44BCN¥6.64BCN¥5.73BCN¥7.78BCN¥10.2B
Revenue growth—+16%-26%-24%—
Gross profitCN¥3.47BCN¥2.64BCN¥2.25BCN¥3.83BCN¥4.72B
EBITDAn/aCN¥1.61BCN¥1.13BCN¥2.70BCN¥3.47B
Net incomeCN¥1.18BCN¥1.13BCN¥949MCN¥2.27BCN¥3.30B
Free cash flow-CN¥703MCN¥330MCN¥280MCN¥2.51BCN¥1.18B
Capital expenditureCN¥1.84BCN¥1.27BCN¥1.13BCN¥1.24BCN¥2.15B
Total debtCN¥689MCN¥524MCN¥475MCN¥572MCN¥585M

Quarterly statements and history in the cockpit →

Asymchem Laboratories (Tianjin) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%4528CYTKIBRXCORTKNSAGRFBANB9926600196AMRXALKS000963ALKEMGLENMARKORKA0126Z0601607002821.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Asymchem Laboratories (Tianjin) is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%20×40×60×4528CORTKNSAGRFBANB600196AMRX000963ALKEMALK-BGLENMARK601607002821.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Asymchem Laboratories (Tianjin) is the large dot.

Asymchem Laboratories (Tianjin) competitors and peer comparison

Head to head with its named competitors (002821.SZ vs 603259.SS vs 300363.SZ vs LONN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Asymchem Laboratories (Tianjin) 002821.SZ$7.27B+20%+18%17%37.4×n/a
WuXi AppTec 603259.SS$64.2B+40%+32%43%17.0×7.2%
Porton Pharma Solutions 300363.SZ$1.66B+37%+6%-2%n/a2.1%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Siegfried SFZN.SW$3.51B-17%+4%16%16.8×n/a

How Asymchem Laboratories (Tianjin) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Asymchem Laboratories (Tianjin) against its 20 peers (data as of 18 Nov 2026)
Measure002821.SZPeer medianRank in peer set
1-month return-8.0%+2.2%6th lowest of 21
6-month return+19.7%-0.4%5th highest of 20
Distance from 52-week high-29.4%-12.9%7th lowest of 21
Revenue growth (TTM)+18.1%+8.5%6th highest of 19
Operating margin17.2%13.7%6th highest of 20
Forward P/E37.4×19.2×2nd most expensive of 16
ROIC minus cost of capital+1.6 pp+1.7 pp9th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%14.8×2.9%+6.6%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%

Questions

Who are Asymchem Laboratories (Tianjin)'s main competitors?
Named competitors: WuXi STA (603259.SS), Porton Pharma (300363.SZ), Lonza (LONN.SW), Siegfried (SFZN.SW). The cockpit's measured peer set (industry) also includes ONO Pharmaceutical (4528.T), Cytokinetics (CYTK), ImmunityBio (IBRX), Corcept Therapeutics (CORT), Kiniksa Pharmaceuticals International (KNSA), Grifols (GRF.MC).
Is Asymchem Laboratories (Tianjin) expensive compared with its peers?
On forward p/e it trades at 37.4× against a peer median of 19.2×, 2nd most expensive of 16 in its peer set.
How has Asymchem Laboratories (Tianjin) stock performed?
Over six months to 18 Nov 2026 the shares returned +19.7% against -0.4% for the median peer; over one year +48.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.